Trial Profile
A phase I, proof of concept trial of LY2439821 in patients with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2016
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- 05 Nov 2010 New trial record.